Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRI-724 + cytarabine
- Development stage
- Phase 2
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Intrathecal
01
Overview
PRI-724 + cytarabine is a combination of **PRI-724**, a small molecule inhibitor that blocks the interaction between CREB-binding protein (CBP) and β-catenin, and **cytarabine**, a pyrimidine nucleoside analog antimetabolite chemotherapy primarily used for the treatment of leukemias. PRI-724 modulates the Wnt/β-catenin signaling pathway, potentially inhibiting self-renewal of cancer stem cells and increasing tumor sensitivity to cytotoxic drugs, while cytarabine disrupts DNA synthesis in rapidly dividing cells by inhibiting DNA polymerase, leading to cancer cell death. This combination is being investigated for its potential to overcome chemotherapy resistance in hematologic malignancies and selected solid tumors[3][5][8].
- Brand names
- Cytosar-UTarabine PFSCytosar
- Other names
- C82C-82C 82cytarabine1-beta-D-Arabinofuranosylcytosinecytosine arabinosidearacytidine
02
Targets
CREBBP (CREB-binding protein)DNA polymerase familyCTNNB1 (Beta-catenin)
Beyond the preview
Go deeper on PRI-724 + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRI-724 + cytarabine.